CDSCO Panel grants AstraZeneca’s Protocol Amendment Proposal for Sodium zirconium cyclosilicate
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment request presented by drug major AstraZeneca Sodium zirconium cyclosilicate. This came after the firm presented Protocol amendment version 3.0 dated 04 Apr 2023 Protocol no. D9487C00001. The study is to evaluate the effect of […]